MBOT
Price
$4.00
Change
-$0.07 (-1.72%)
Updated
Aug 28, 04:45 PM (EDT)
Capitalization
185.37M
71 days until earnings call
MNOV
Price
$1.35
Change
+$0.01 (+0.75%)
Updated
Aug 28, 04:40 PM (EDT)
Capitalization
66.7M
77 days until earnings call
Interact to see
Advertisement

MBOT vs MNOV

Header iconMBOT vs MNOV Comparison
Open Charts MBOT vs MNOVBanner chart's image
Microbot Medical
Price$4.00
Change-$0.07 (-1.72%)
Volume$11.88K
Capitalization185.37M
Medicinova
Price$1.35
Change+$0.01 (+0.75%)
Volume$300
Capitalization66.7M
MBOT vs MNOV Comparison Chart in %
Loading...
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 6.85B. The market cap for tickers in the group ranges from 658 to 184.32B. TMO holds the highest valuation in this group at 184.32B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 2%. For the same Theme, the average monthly price growth was 11%, and the average quarterly price growth was 36%. EQ experienced the highest price growth at 68%, while BTAI experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was 9%. For the same stocks of the Theme, the average monthly volume growth was 13% and the average quarterly volume growth was 14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 53
SMR Rating: 87
Profit Risk Rating: 90
Seasonality Score: -23 (-100 ... +100)

Market Cap

The average market capitalization across the group is 126.04M. The market cap for tickers in the group ranges from 66.7M to 185.37M. MBOT holds the highest valuation in this group at 185.37M. The lowest valued company is MNOV at 66.7M.

High and low price notable news

The average weekly price growth across all stocks in the group was 13%. For the same group, the average monthly price growth was 16%, and the average quarterly price growth was 85%. MBOT experienced the highest price growth at 23%, while MNOV experienced the biggest fall at 2%.

Volume

The average weekly volume growth across all stocks in the group was 1,889%. For the same stocks of the group, the average monthly volume growth was 68% and the average quarterly volume growth was 878%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 100
Price Growth Rating: 46
SMR Rating: 96
Profit Risk Rating: 100
Seasonality Score: 9 (-100 ... +100)
VS
MBOT vs. MNOV commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBOT is a Hold and MNOV is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (MBOT: $4.07 vs. MNOV: $1.34)
Brand notoriety: MBOT and MNOV are both not notable
MBOT represents the Pharmaceuticals: Other, while MNOV is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBOT: 126% vs. MNOV: 669%
Market capitalization -- MBOT: $185.37M vs. MNOV: $66.7M
MBOT [@Pharmaceuticals: Other] is valued at $185.37M. MNOV’s [@Biotechnology] market capitalization is $66.7M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $170.01B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $10.96B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNOV’s FA Score shows that 0 FA rating(s) are green whileMBOT’s FA Score has 0 green FA rating(s).

  • MNOV’s FA Score: 0 green, 5 red.
  • MBOT’s FA Score: 0 green, 5 red.
According to our system of comparison, MBOT is a better buy in the long-term than MNOV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBOT’s TA Score shows that 6 TA indicator(s) are bullish while MNOV’s TA Score has 6 bullish TA indicator(s).

  • MBOT’s TA Score: 6 bullish, 4 bearish.
  • MNOV’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both MBOT and MNOV are a good buy in the short-term.

Price Growth

MBOT (@Pharmaceuticals: Other) experienced а +22.96% price change this week, while MNOV (@Biotechnology) price change was +2.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.10%. For the same industry, the average monthly price growth was +5.04%, and the average quarterly price growth was +21.44%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.08%. For the same industry, the average monthly price growth was +14.69%, and the average quarterly price growth was +30.34%.

Reported Earning Dates

MBOT is expected to report earnings on Nov 07, 2025.

MNOV is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+4.10% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+2.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MBOT($185M) has a higher market cap than MNOV($66.7M). MBOT YTD gains are higher at: 263.393 vs. MNOV (-36.190). MNOV (-13.28M) and MBOT (-13.4M) have comparable annual earnings (EBITDA) . MNOV (34.3M) and MBOT (32.7M) have equal amount of cash in the bank . MBOT has less debt than MNOV: MBOT (149K) vs MNOV (302K). MNOV has higher revenues than MBOT: MNOV (135K) vs MBOT (0).
MBOTMNOVMBOT / MNOV
Capitalization185M66.7M277%
EBITDA-13.4M-13.28M101%
Gain YTD263.393-36.190-728%
P/E RatioN/AN/A-
Revenue0135K-
Total Cash32.7M34.3M95%
Total Debt149K302K49%
FUNDAMENTALS RATINGS
MNOV vs MBOT: Fundamental Ratings
MNOV
MBOT
OUTLOOK RATING
1..100
1123
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
5735
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
19n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBOT's Valuation (58) in the Biotechnology industry is in the same range as MNOV (69). This means that MBOT’s stock grew similarly to MNOV’s over the last 12 months.

MBOT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MNOV (100). This means that MBOT’s stock grew similarly to MNOV’s over the last 12 months.

MNOV's SMR Rating (95) in the Biotechnology industry is in the same range as MBOT (98). This means that MNOV’s stock grew similarly to MBOT’s over the last 12 months.

MBOT's Price Growth Rating (35) in the Biotechnology industry is in the same range as MNOV (57). This means that MBOT’s stock grew similarly to MNOV’s over the last 12 months.

MBOT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MNOV (100). This means that MBOT’s stock grew similarly to MNOV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBOTMNOV
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
MBOT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IEHC9.200.20
+2.22%
IEH Corp.
CNDAU12.99N/A
N/A
Concord Acquisition Corp II
MRPMF0.04N/A
N/A
MARCO POLO MARINE LTD.
BTSNY17.38N/A
N/A
Betsson AB
SWRBY7.47-0.69
-8.45%
Swire Pacific Ltd.

MBOT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with POAI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then POAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBOT
1D Price
Change %
MBOT100%
+4.90%
POAI - MBOT
37%
Loosely correlated
+2.69%
BNGO - MBOT
35%
Loosely correlated
-2.26%
CORBF - MBOT
33%
Loosely correlated
-40.00%
RCEL - MBOT
33%
Poorly correlated
-0.66%
OTCFF - MBOT
32%
Poorly correlated
+3.76%
More

MNOV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with FATE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
-1.47%
FATE - MNOV
36%
Loosely correlated
+0.90%
MNKD - MNOV
30%
Poorly correlated
+11.06%
VIR - MNOV
29%
Poorly correlated
+17.79%
TIL - MNOV
28%
Poorly correlated
-1.44%
QLGN - MNOV
28%
Poorly correlated
-1.69%
More